Chronic progressive nephropathies and modern lifestyle

References

  1. Ritz Е., Orth S. R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999; 341: 1127-1133.
  2. Keane W. F., Brenner В. М., de Zeeeuw D. et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int. 2003; 63: 1499-1507.
  3. Мухин H А., Шоничев Д. Г., Балкаров И. М. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Тер. арх. 1999; 6: 12- 24.
  4. Щербак А. В., Балкаров И. М., Козловская Л. В. и др. Фибринолитическая активность мочи как показатель поражения почек при нарушении обмена мочевой кислоты. Тер. арх. 2001; 6: 34-37.
  5. Farquharson С. A. J., Butler R., Hill A. et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circu- lation 2002; 106: 221-226.
  6. Mazzali M., Hughes J., Kim Y.-H. et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
  7. Kang D.-H., Nakagawa Т., Feng L. et al. A role of uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002; 13: 2888-2897.
  8. Verdecchia P., Schillaci G., Reboldi G.-P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study. Hypertension 2000; 36: 1072- 1078.
  9. Alderman M. H., Cohen H., Madhavan S., Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
  10. Мухин Н. А. Профилактическая нефрология и образ жизни современного человека. Тер. арх. 1993; 6: 4-7.
  11. Мухин Н. А., Балкаров И. М., Моисеев С. В. и др. Урикозурическое действие лозартана. Клин, фармакол. и тер. 2003; 12 (5): 55-58.
  12. Pfeffer M., Swedberg К., Granger С. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759-766.
  13. Eaton S. В., Konner M. Paleolithic nutrition. N. Engl. J. Med. 1985; 312: 283-289.
  14. Watanabe S., Kang D.-H., Feng L. et al. Uric acid, hominoid evolution and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360.
  15. Тареев Е. М. Гломерулонефриты. Общие вопросы. Клиника. В кн.: Тареева И. Е. (ред.) Нефрология: Руководство для врачей. М.; 2000. 188-205.
  16. Guyton А. С, Coleman Т. G, Cowley А. V. et al. Arterial pressure regulation. Overridding dominance of the kidneys in long-term regulation and in hypertension. Am. J. Med. 1972; 52: 584-594.
  17. Stamler J. The INTERSALT Study: backgrounds, methods, findings and implications. Am. J. Clin. Nutr. 1997; 65: 626S- 642S.
  18. Tuomilehto J., Jousilahti P., Rastenyte D. et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet 2001; 357: 848-851.
  19. Cusi D., Bartassina C, Azzani T. et al. Polymorphisms of aadducin and salt-sensitivity in patients with essential hypertension. Lancet 1997; 349: 1338-1339.
  20. Hunt S. C, Cook N. R., Oberman A. et al. Angiotensionogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention phase II. Hypertension 1998; 32: 393-401.
  21. Whelton P. K, Appel L. J., Espeland M. A. et al. Sodium restriction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of non-pharma cological interventions in the elderly (TONE). J. A. M. A. 1998; 279: 839-846.
  22. Sacks F. M., Svetkey L. P., Vollmer W. M. et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N. Engl. J. Med. 2001; 344: 3-10.
  23. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-1608.
  24. Kenchaiah S., Evans J. C, Levy D. et al. Obesity and the risk of heart failure. N. Engl. J. Med. 2002; 347: 305-313.
  25. Praga M., Hernandez E-, Herrero J. С et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000; 58: 2111-2118.
  26. Chagnac A., Weinstein Т., Korzets A. et al. Glomerular hemodynamics in severe obesity. Am. J. Renal Physiol. 2000; 278: F817-F822.
  27. Wolf G., Chen S., Han D. C, Ziyadeh F. N. Leptin and renal disease. Am. J. Kidney Dis. 2002; 39: 1-11.
  28. Maddox D. A., Alavi F. K., Santella R. N., Zawada E. T. Prevention of obesity-linked renal disease: agedependent effects of dietary food restriction. Kidney Int. 2002; 62: 208-219.
  29. Orth S. R. Smoking - a renal risk factor. Nephron 2000; 86: 12-26.
  30. Baigent C, Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152.
  31. Goerre S., Staehli C, Shaw S., Luscher T. F. Effect of sigarette smoking and nicotine on plasma endothelin-1 levels. J. Cardiovasc. Pharmacol. 1995; 26: S236-S238.
  32. Sawicki P. Т., Didjurgeit U., Muhlhauser I. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126-131.
  33. Ward M. M., Studenski S. Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch. Intern. Med. 1992; 152: 2028-2048.
  34. Stengel В., Couchod C, Lenee S., Hemon D. Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney Int. 2000; 57: 2519-2526.
  35. Zuccala A., Zuccheli P. Ischemic nephropathy: diagnosis and treatment. J. Nephrol. 1998; 11: 318-324.
  36. Jorenby D. E., Leischow S. J., Nides M. A. et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340: 685-691.
  37. Тареева И. Е., Андросова С. О. Влияние ненаркотических анальгетиков и нестероидных противовоспалительных препаратов на почки. Тер. арх. 1999; 6: 17-21.
  38. Komers R., Anderson S., Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am. J. Kidney Dis. 2001; 38: 1145-1157.
  39. Morales E., Mucksavage J. J. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy 2002; 10: 1317-1321.
  40. Hay E., Derazon H, Bukish N. et al. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J. Emerg. Med. 2002; 22: 349- 352.
  41. Rocha J. L., Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001; 357: 1946-1947.
  42. Whelton A., Fort J. G., Puma J. A. et al. Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 2001; 8: 85-95.
  43. Тареев Е. М. Хронический гломерулонефрит. В кн.: Tape- ев Е. М. (ред.) Основы нефрологии. М.; 1972. 402-403.

Statistics

Views

Abstract - 81

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2003 Mukhin N.A., Balkarov I.M., Moiseev S.V., Fomin V.V., Lebedeva M.V., Krasnova E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies